HBMN:SWX
HBM Healthcare Investments AG
223,00 CHF
arrow_downward
-0,22%(-0,50) 1D
13. nov., 17.30.01 GMT+1 · CHF
search
Alle symboler
| Symbol | Pris | Ændring | Ændring i % |
|---|
insights_autoGenererer vigtig indsigt for HBMN...
Åbn
223,50 CHF
Høj
225,00 CHF
Lav
221,00 CHF
Markedsværdi
1,48 mia.
Gns. vol.
5,91 t
Volumen
0,00
Udbytte
4,04 %
Kvartalsvis udbytte
2,25 CHF
Ex-dato
17. jun. 2026
P/E-forhold
4,19
Højeste i 52 uger
258,00 CHF
Laveste i 52 uger
198,60 CHF
Indtægt pr. aktie
53,19 CHF
Aktier i omløb
6,62 mio.
Åbn
223,50 CHF
Høj
225,00 CHF
Lav
221,00 CHF
Markedsværdi
1,48 mia.
Gns. vol.
5,91 t
Volumen
0,00
Udbytte
4,04 %
Kvartalsvis udbytte
2,25 CHF
Ex-dato
17. jun. 2026
P/E-forhold
4,19
Højeste i 52 uger
258,00 CHF
Laveste i 52 uger
198,60 CHF
Indtægt pr. aktie
53,19 CHF
Aktier i omløb
6,62 mio.
Nyhedshistorier
Fra webkilder og nyhedspartnere
investingLive
·
for 1 time siden
Morgan Stanley goes max overweight global stocks, sees 15% S&P 500 upside on AI capex
Yahoo Finance
·
for 1 time siden
Dow, S&P 500, Nasdaq Futures Edge Lower As Markets Brace For Nvidia Earnings, Anthropic IPO, Fed Minutes: SMMT, NBIS, HELP, MSTR In Focus
The Motley Fool
·
for 8 timer siden
This Dividend King Yields 5 Times the S&P 500. Is It a Buy Now?
BigGo Finance
·
for 14 timer siden
Goldman Sachs Sets 8,700 S&P 500 Target for 2027, Sees 14% Upside as AI Capex Peaks
Profil
HBM Healthcare Investments is a publicly traded Swiss investment and venture capital firm focusing on emerging technologies in the global healthcare sector. Within healthcare their focus is predominantly in biotechnology, medical technology, diagnostics, therapeutics and digital health.
A 2022 article in Swiss daily Luzerner Zeitung profiled HBM and interviewed its CEO, and described the company’s investment strategy as focused on early-stage but post-seed round opportunities.
Founded in July 2001 as HBM Bioventures AG by former Roche Chief Financial Officer Henri B. Meier who was its first Chairperson of the Board. A Handelszeitung article from 2020 described Meier's goal when founding the company as to profit from the "thesis" that from the 2000s onwards "Big Pharma is doing less and less research and development itself and is instead acquiring promising biotech companies" In an analysis of how HBM was put together, Swiss magazine Finanz und Wirtschaft described how he was able to raise almost 500 million Swiss Francs for the company launch. HBM is based in Zug and managed by HBM Partners. HBM acquired rival Swiss VC International BM Biomedicine in 2005. Wikipedia
Om HBM Healthcare Investments AG
Administrerende direktør-
Ansatte-
Grundlagt12. jul. 2001
HovedsædeZug, Kanton Zug, Schweiz
SektorFinancials
Branche-
Websitehbmhealthcare.com